CLINICAL_TRIALS
withdrawal
· 2017-04-20
Clinical Trial Update: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS [Phase 3]
Summary
Phase 3 trial evaluating NVA237 (umeclidinium) as an add-on to fixed-dose LABA/ICS for COPD has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: WITHDRAWN